Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Statement of the Deutsche Ophthalmologische Gesellschaft (German Ophthalmological Society), the Retinologische Gesellschaft (German Retina Society) and the Berufsverband der Augenärzte Deutschlands (German Professional Association of Ophthalmologists) on the therapy of choroidal neovascularization in myopia. State: March 2014].

× No keyword cloud information.

31 in total

1. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results.

Authors: Rufino M Silva; José M Ruiz-Moreno; Paulo Rosa; Angela Carneiro; João Nascimento; Luís F Rito; M Luz Cachulo; Fausto Carvalheira; Joaquim N Murta
Journal: Retina Date: 2010-03 Impact factor: 4.256

2. [New aspects in the therapy of neovascular age related macular degeneration. Current position of the Retinological Society, the Germany Ophthalmologic Society and the Professional Union of Eye Doctors of Germany].

Authors:
Journal: Ophthalmologe Date: 2009-05 Impact factor: 1.059

Review 3. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia.

Authors: Salomon Y Cohen
Journal: Retina Date: 2009-09 Impact factor: 4.256

4. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.

Authors: Pierluigi Iacono; Maurizio Battaglia Parodi; Alessandro Papayannis; Stylianos Kontadakis; Saumil Sheth; Maria Lucia Cascavilla; Francesco Bandello
Journal: Retina Date: 2012-09 Impact factor: 4.256

5. Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years?

Authors: Bogomil Voykov; Faik Gelisken; Werner Inhoffen; Michael Voelker; Karl Ulrich Bartz-Schmidt; Focke Ziemssen
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2010-01-29 Impact factor: 3.117

Review 6. Laser photocoagulation for choroidal neovascularisation in pathologic myopia.

Authors: G Virgili; F Menchini
Journal: Cochrane Database Syst Rev Date: 2005-10-19

Review 7. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation.

Authors: Takayuki Baba; Mariko Kubota-Taniai; Masayasu Kitahashi; Kyoko Okada; Yoshinori Mitamura; Shuichi Yamamoto
Journal: Br J Ophthalmol Date: 2009-12-03 Impact factor: 4.638

8. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.

Authors: Lazaros Konstantinidis; Irmela Mantel; Jean-Antoine C Pournaras; Leonidas Zografos; Aude Ambresin
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2008-11-29 Impact factor: 3.117

9. Myopia, axial length, and age-related cataract: the Singapore Malay eye study.

Authors: Chen-Wei Pan; Pui Yi Boey; Ching-Yu Cheng; Seang-Mei Saw; Wan Ting Tay; Jie Jin Wang; Ava Grace Tan; Paul Mitchell; Tien Yin Wong
Journal: Invest Ophthalmol Vis Sci Date: 2013-07-02 Impact factor: 4.799

10. Photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: a randomized clinical trial.

Authors: David Maberley
Journal: Ophthalmology Date: 2009-09-12 Impact factor: 12.079

2 in total

Review 1. [Secondary diseases in high myopia].

Authors: F Ziemssen; W Lagrèze; B Voykov
Journal: Ophthalmologe Date: 2017-01 Impact factor: 1.059

2. [Baseline diagnostics and initial treatment decision for anti-vascular endothelial growth factor treatment in retinal diseases : Comparison between results by study physician and reading centers (ORCA/OCEAN study)].

Authors: Christian K Brinkmann; Petrus Chang; Tina Schick; Britta Heimes; Jessica Vögeler; Birgit Haegele; Bernd Kirchhof; Frank G Holz; Daniel Pauleikhoff; Focke Ziemssen; Sandra Liakopoulos; Georg Spital; Steffen Schmitz-Valckenberg
Journal: Ophthalmologe Date: 2019-08 Impact factor: 1.059

2 in total